These monoclonal antibodies enhance T-cell activation and improve tumor suppression through disinhibiting immune response signaling components such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) [1]. This evidence concerns the gene PDCD1 and neoplasm.